Background/Objectives: To compare the efficacy of single versus multiple doses of plant sterols on circulating lipid level and cholesterol trafficking. Subjects/Methods: A randomized, placebo-controlled, three-phase (6 days/phase) crossover, supervised feeding trial was conducted in 19 subjects. Subjects were provided (i) control margarine with each meal; (ii) 1.8 g/day plant sterols in margarine with breakfast (single-BF) and control margarine with lunch and supper or (iii) 1.8 g/day plant sterols in margarine divided equally at each of the three daily meals (three times per day). Results: Relative to control, end point plasma low-density lipoprotein (LDL) cholesterol concentrations were lower (Po0.05) after consuming plant sterols three times per day but were not different when consumed once per day (3.43±0.62, 3.22±0.58 and 3.30 ± 0.65 mmol/l, control, three times per day and single-BF, respectively). Relative to the control, end point LDL level was 0.21±0.27 mmol/l (6%) lower (Po0.05) at the end of the three times per day phase. Cholesterol fractional synthesis rate was highest (Po0.05) after the three times per day phase (0.0827 ± 0.0278, 0.0834 ± 0.0245 and 0.0913 ± 0.0221 pool/day, control, single-BF and three times per day, respectively). Cholesterol-absorption efficiency decreased (Po0.05) by 36 and 39% after the three times per day and single-BF phase, respectively, relative to control. Conclusions: Present data indicate that to obtain optimal cholesterol-lowering impact, plant sterols should be consumed as smaller doses given more often, rather than one large dose.
Introduction
The National Cholesterol Education Panel and the American Heart Association have suggested the use of plant sterols and stanols, the hydrogenated form of sterols, as an approach to control circulating levels of low-density lipoprotein (LDL) cholesterol (Cleeman et al., 2001; Fletcher et al., 2005) . Plant sterols and stanols suppress cholesterol absorption consequently increasing cholesterol synthesis, with a net effect of reducing LDL-cholesterol concentrations by about 10 percent (Gylling and Miettinen, 1994; Jones et al., 2000; Vanstone et al., 2002; Katan et al., 2003) .
The majority of studies have shown efficacy of plant sterol supplementation when distributed in two (Weststrate and Meijer, 1998; Hallikainen et al., 2000a; Maki et al., 2001; Ntanios, 2001) or three Mensink et al., 2002; Vanstone et al., 2002) doses per day. Discordant data exist, however, on the effect of a single dose of plant sterols on plasma cholesterol concentrations. A single dose of plant sterol has been shown to lower cholesterol levels to a similar extent as multiple doses of the same amount . hypothesized that plant stanols remain in the intestinal lumen for extended periods where they decrease cholesterol absorption, thus it is not necessary to consume plant stanol ester products throughout the day. It has also been reported that a single dose of plant sterol failed to lower LDLcholesterol concentrations when given as a single morning administration (AbuMweis et al., 2006) . Results from the study by AbuMweis et al. (2006) do not support the hypothesis by and suggest that the dosing frequency of plant sterols or the time of intake of single dose of plant sterols could affect their cholesterol-lowering action. Nonetheless, current marketing of plant sterol-containing products is largely directed toward consumption once a day with breakfast meals. To date, no studies have examined the effects of plant sterol consumption frequency on circulating lipid profiles and cholesterol kinetics as part of a controlled low-fat, low-cholesterol diet. The objective of this study was, therefore, to compare under controlled and supervised conditions the effect of a standardized dose of plant sterols given once in the morning or three times throughout the day on plasma lipids and cholesterol kinetics.
Subjects and methods

Subjects
Male and postmenopausal female subjects 40-80 years with a body mass index between 22 and 32 kg/m 2 were recruited from a database of subjects who had participated in previous studies at the Mary Emily Clinical Nutrition Research Unit of McGill University. Respondents underwent a thorough historical and physical examination to exclude those with thyroid disease, diabetes mellitus, kidney disease, liver disease, smokers or consumption of alcohol at 414 drinks per week. Volunteers taking medication known to affect lipid metabolism, high-dose dietary supplements, fish oil capsules or plant sterol for 3 months or more prior to the start of the study were excluded from participation. At the first visit, volunteers were screened for LDL cholesterol 43.0 mmol/l. Eligible volunteers were asked to return for a second screening to measure complete blood counts, serum biochemistry and lipid profiles that included total cholesterol, triacylglycerol, LDL-cholesterol and high-density lipoprotein cholesterol levels.
Study design and protocol
A randomized, single-blind crossover placebo-controlled clinical trial was carried out at the Mary Emily Clinical Nutrition Research Unit. The study consisted of three phases of 6 days each. During day 1 through to day 5, subjects consumed a precisely controlled weight-maintaining diet. At the end of each phase, that is day 6, blood samples were collected but no diets were provided. The three phases of treatments included control phase: no plant sterols were consumed (control); single morning dose phase: plant sterol dose was given only at breakfast (single-BF); and three times dose phase: the same plant sterol dose was divided equally among three daily meals, breakfast, lunch and supper (three times per day). Each phase was separated by a washout period of 2 weeks during which time the subjects consumed their habitual diets. Subjects were randomly assigned to one of six predetermined treatment sequences using a Latin square design. Diets were prepared in the metabolic kitchen of the Mary Emily Clinical Nutrition Research Unit where foods were weighed to the nearest 0.5 g. Three isocaloric meals were prepared each day for the five study days for every subject during each phase. Total caloric intake was matched to each subject's energy requirements. Diets were designed to contain 55% of energy (E) from carbohydrates, 15% E from protein and 30% E from fat, 80 mg/1000 kcal of cholesterol and 12 g/1000 kcal of fibers. During the study period, subjects weighed themselves every morning. Subjects consumed breakfasts and the suppers at the Mary Emily Clinical Nutrition Research Unit under supervision. The lunch meals were packed to be taken out. Plant sterol-enriched margarine (Take Control-Unilever Inc., Vlaardingen, The Netherlands) was used to provide a dose of 1.8 g/day of plant sterols, and the same margarine without plant sterols served as the control margarine (Table 1) . For the single-BF phase, the plant sterol-enriched margarine was incorporated in the breakfast meal and the control margarine was incorporated in the lunch and supper meals. During the divided phase, plant sterol-enriched margarine was divided equally among the breakfast, lunch and supper meals.
Subjects consumed a controlled diet including the assigned study treatment from day 1 to day 5. On the second day (24 h) of each phase, subjects ingested 75 mg [3, [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] C] cholesterol (CDN Isotopes; Montreal) to and consumed on a slice of toast. On day 5 of each feeding period, approximately 25 ml of deuterium oxide was given orally to each subject before breakfast to measure endogenous cholesterol synthesis. Fasting blood samples were taken at baseline prior to isotope administration (24 h) as well as on days 3, 4, 5 and 6 to monitor enrichment levels of both isotopes.
Analyses Plasma lipid profile. Fasting blood samples collected on days 5 and 6 were used to measure circulating lipid concentrations. Blood was centrifuged for 20 min at 520 Â g and 4 1C to separate plasma from red blood cells (RBCs). Plasma total and high-density lipoprotein cholesterol, and triacylglycerol concentrations were measured using standardized procedures as previously described (Lichtenstein et al., 2006) . The Friedewald equation was used to calculate LDL-cholesterol concentrations (Friedewald et al., 1972) .
Cholesterol-absorption determination. Cholesterol absorption was assessed using the stable isotope single-tracer method as previously described (Ostlund et al., 1999 (Ostlund et al., , 2002 Spilburg et al., 2003; Shin et al., 2005; Varady and Jones, 2006) . It was reported that the area under the 13 C-enrichment curve, as measured by the single-tracer method, correlates with cholesterol absorption rate as measured by the dual stable isotope ratio method (Wang et al., 2004) . Compared to the dual stable isotope ratio method, the single stable isotope single-tracer method is less invasive. Free cholesterol extracted (Folch et al., 1957) from RBCs was used to determine 13 C-cholesterol enrichments using on-line gas chromatography/combustion/isotope ratio mass spectrometry. Lipids extracted were dissolved in hexane and injected into a gas chromatograph (Agilent 6890N) interfaced with a Finnigan Delta V Plus isotope ratio mass spectrometer (Bremen, Germany) through a Finnigan combustion interface (Combustion Interface III; Bremen). Isotope abundance, expressed in delta (d) per mil (%), was calculated using CO 2 as a reference gas. The d values were further expressed relative to the international reference standard, Pee Dee Belemnite limestone, using a calibration curve of working standards that were analyzed previously using a conventional isotope ratio mass spectrometry (SIRA 12; Isomass, Cheshire, United Kingdom). Endogenous cholesterol-synthesis determination. Cholesterol synthesis rates were assessed after 24 h of deuterium water administration, using the deuterium incorporation approach (Jones et al., 1993) . This method measures cholesterol synthesis as the rate of deuterium incorporation from body water into RBC membrane free cholesterol over a 24-h period. The deuterium incorporation method has been validated against the sterol balance method (Jones et al., 1998a) and mass isotopomer distribution analysis (Di Buono et al., 2000) . Deuterium enrichment was measured in both RBC free cholesterol and plasma water. Enrichments were expressed relative to standard mean ocean water and a series of standards of known enrichment.
The measurement of free-cholesterol deuterium enrichment was performed using online gas chromatography/ pyrolysis/isotope ratio mass spectrometry as described above. Lipids were extracted from RBCs as described above for cholesterol-absorption determination. Isotope abundance, expressed in d %, was calculated using H 2 as reference gas.
The d values were further expressed relative to standard mean ocean water using a calibration curve of working standards.
Fractional synthesis rate (FSR) is taken to represent RBC free-cholesterol deuterium enrichment values relative to the corresponding mean plasma water sample enrichment after correcting for the free-cholesterol pool. FSR represents that fraction of the cholesterol pool that is synthesized in 24 h and is calculated as per the equation (Jones et al., 1993) :
where del for deuterium is the enrichment difference between free cholesterol and plasma water between 72 h (day 5) and 96 h (day 6) in parts per thousand relative to a standard mean ocean water standard. The factor 0.478 accounts for the ratio of labelled H atoms replaced by deuterium (22/46) during in vivo biosynthesis. Cholesterol absolute synthesis rates (ASR) were calculated as follows:
Statistics All data are expressed as means ± s.d. Statistical analysis was carried out using SAS (version 8.0; SAS Institute Inc., Cary, NC, USA). The principal statistical model used was the analysis of variance taking into account subject as a random effect, study treatment effect, period effect, sequence effect and carryover effect. Residuals of every outcome were checked for normality using Shapiro-Wilk test. If the normality assumption was violated for a variable, then log transformation was performed. In the event of a statistically significant treatment effect (P-valueo0.05), pair-wise comparisons were performed using Tukey's test. Tests for associations between variables were performed using Pearson Correlation Coefficient analyses.
Results
Characteristics of the study subjects are provided in Table 2 . There were no significant weight changes across any of the study phases. Concentrations of plasma lipids and lipoproteins at the end of each treatment phase are shown in Table 3 . End point plasma LDL-cholesterol concentrations were 3.43±0.62, 3.22±0.58 and 3.30±0.65 mmol/l after control, three times per day and single-BF, respectively. Relative to the control, end point plasma LDL-cholesterol level was 0.21±0.27-mmol/l (6%) lower (Po0.05) at the end of the three times per day phase and not significantly different at the end of the single-BF phase compared to control. Total cholesterol tended to be lowest (P ¼ 0.0639) during the three times per day phase whereas plasma highdensity lipoprotein and triacylglycerol concentrations were not different among the study treatments. The total cholesterol/high-density lipoprotein ratio was lower (Po0.05) at the end of the three times per day phase by 4.4%, relative to control phase. Cholesterol absorption AUC (24-96 h) of RBC cholesterol during the single-BF phase and three times per day phase was lower by 39 and 36%, respectively, compared to the control phase (Table 4) . Similarly, E-max values were lower (Po0.0001) during the single-BF phase and three times per day phase than the control phase. When subjects were analyzed by treatment grouping, the change in LDL relative to the control phase tended to be associated with the change in AUC (24-96 h) relative to the control phase for the three times per day phase (r ¼ 0.43, P ¼ 0.0623), but not for the single-BF phase (P ¼ 0.4858). Maximum values for 13 C enrichment were attained at around 48 h (Figure 1 ). Cholesterol FSR and ASR values were highest (Po0.05) during the plant sterol three times per day phase (Table 4) . 
Plant sterols and cholesterol trafficking SS AbuMweis et al
Discussion
The novel finding of this study is that consumption of a single morning dose of plant sterols was not as efficacious in lowering LDL concentrations as was the three times per day dosing pattern. Most noticeably, a reduction in plasma LDL concentration was achieved after a relatively short intervention period. Previous studies have reported a reduction in cholesterol concentrations after 1 day (Miettinen et al., 2000) , 8 days (Hallikainen et al., 2002) and 10 days (Jones et al., 1998b) of plant sterol/stanol consumption. However, the single-day study by Miettinen et al. (2000) was carried out in colectomized individuals whose cholesterol metabolism differed from that of healthy individuals. The 8-day study of Hallikainen et al. (2002) lacked a control group, and the reduction in serum cholesterol concentrations by stanol ester consumption was relative to baseline values; thus a time effect could have contributed to the reduction in cholesterol concentrations. Although the duration of the present study was relatively short, plant sterol ester lowered LDL-cholesterol concentrations by 0.21 mmol/l (6%). The magnitude of reduction in LDL-cholesterol concentrations observed in the current study is consistent with that typically observed after several 3-to 6-week intervention periods (Hendriks et al., 1999; Sierksma et al., 1999; Colgan et al., 2004; Jakulj et al., 2005; Kratz et al., 2007) or even for 52 weeks (Hendriks et al., 2003) . Nonetheless, there is some evidence that even this modest reduction in circulating levels of cholesterol may decrease the risk of developing cardiovascular disease (Muldoon et al., 1990) . Also, the addition of plant sterol/stanol margarine to statin therapy has an additive effect on reduction in LDL-cholesterol levels, serving as an alternative approach to doubling the statin dose, without increasing costs, and in side effects that usually accompany an increase in statin dose (Vorlat et al., 2003) . Doubling the dose of statin normally produces a further reduction of about 6% in LDL-cholesterol levels (Blair et al., 2000) .
Limited data are available on the effect of dosing frequency of plant sterols on lipid profiles and cholesterol kinetics. An earlier study demonstrated that 2.5 g/day of plant stanol consumed for 4 weeks once per day at lunch or divided among three meals, 0.42 g at breakfast, 0.84 g at lunch and 1.25 g at supper, lowered LDL-cholesterol concentrations to a similar extent, about 10% . A more recent study reported that consuming a single dose of plant sterols provided in a yoghurt drink with lunch resulted in a larger decrease in LDL-cholesterol concentrations than consuming the same dose with breakfast (Doornbos et al., 2006) .
In addition to monitoring changes in plasma cholesterol concentration, the mechanism(s) accounting for these changes were also assessed. In accordance with previous work, administration of plant sterols at a dose of 1.8 g/day was shown to significantly decrease intestinal cholesterolabsorption efficiency. Cholesterol FSR increased only during the three times per day phase. Previous studies utilizing different experimental approaches have shown that consumption of plant sterols/stanols reduced cholesterol absorption and consequently increased cholesterol synthesis, with a net reduction in LDL-cholesterol concentrations in hypercholesterolemic individuals (Gylling and Miettinen, 1994; Jones et al., 2000; Vanstone et al., 2002) . The regulatory process behind this phenomenon is not clearly understood yet.
Plant sterols consumed during the single-BF phase reduced cholesterol-absorption efficiency, as measured by the stable isotope single-tracer method, but did not reduce LDLcholesterol concentrations compared to control. It is possible that gut cholesterol pools did not have enough time to adjust for changing in cholesterol absorption caused by the consumption of plant sterols at different dosage frequency. The discrepancy may be due to the method used to assess cholesterol absorption efficiency. The single-tracer method measures only the efficiency of cholesterol absorption rather than the absolute amount of absorbed cholesterol that depends on endogenous biliary cholesterol secretion (Ostlund et al., 2002) . Some studies have shown that the consumption of plant sterols/stanols increases biliary secretion of cholesterol (Becker et al., 1992; Gylling and Miettinen, 1994; Miettinen and Vanhanen, 1994) . Whether the frequency of intake of plant sterols affects the absolute amount of cholesterol absorbed and/or bile acid excretion was not assessed. It is our assumption that if the dietary intake of cholesterol and fat was maintained constant across periods, then it would be anticipated that the rate of rise of tracer in blood should reflect not only fractional absorption but also total mass of sterol taken up from the gut. It is, however, understood that shifts, for instance, in biliary sterol excretion could impact the net amount of cholesterol absorbed. Additional experiments should be carried out using the intestinal infusion technique to assess whether the frequency of intake of plant sterols affects the absolute amount of cholesterol absorbed and/or bile acid excretion. In addition, the observed reduction in efficiency of dietary cholesterol absorption may not always reflect the magnitude of reduction in circulating cholesterol. This explanation is supported by a finding from previous work. Jones et al. (2000) reported no difference in cholesterol absorption between plant sterol-and plant stanol-containing diets, although the decline in LDL-cholesterol levels was greater at the end of plant sterol, compared to the plant stanol phase. Gylling et al. (1997) have shown that the sitostanol-induced changes in LDL cholesterol were significantly associated with the change in cholesterol-absorption efficiency (r ¼ 0.443). Likewise, Jones et al. (2000) reported an r ¼ 0.530 between plasma total cholesterol concentrations and cholesterolabsorption coefficient with plant sterol treatment. In the present study, the changes in LDL-cholesterol concentration tended to be associated with changes in AUC of 13 Ccholesterol when plant sterols were consumed three times a day. The proportion of the total variation in circulating total and LDL-cholesterol concentrations that is explained by cholesterol-absorption efficiency in the present study and prior studies (Gylling et al., 1997; Jones et al., 2000) ranges from 18 to 28%. These findings suggest that either the methods used to measure absorption are insensitive to changes in cholesterol-absorption efficiency or plant sterols/ stanols reduce circulating levels by other means. Notably, cholesterol FSR was highest during the three times per day phase, likely in response to the decrease in cholesterolabsorption efficiency. On the contrary, no reciprocal increase in cholesterol synthesis in response to the decrease in absorption during the single-BF phase was observed. It is likely that many changes were taking place in the process of cholesterol absorption and these changes were not detected by the single-tracer method. It remains to be assessed if the data obtained in the present investigation will be different if the oral isotope is to be given in three divided daily doses and not as a single bolus. The single stable isotope singletracer method has not been validated under conditions that might affect cholesterol absorption, including effect of multiple oral dosages, time of intake of single oral dose, the effect of low and high cholesterol diets and the effect of preand post-test dietary intake of cholesterol. Nevertheless, results of this study have implications for the mechanism of action of plant sterols as cholesterol-lowering agents. In contrast to the hypothesis that plant sterols/ stanols are retained in the enterocyte, it does not appear that a single dose consumed early in the morning is as efficacious as the same dose divided across multiple meals. Recent work suggests that the AUC (24-96 h) of RBC 13 C-cholesterol and E-max values when single dose of plant sterols was consumed with supper was similar to control values (unpublished data, S AbuMweis et al.). Cholesterol absorption is a gradual process as labeled cholesterol usually peaks after 48 h of administration (Bosner et al., 1993) , and the ingested dietary cholesterol is secreted by the small intestine in chylomicrons into the circulation during X3 subsequent postprandial periods in human (Beaumier-Gallon et al., 2001) . Thus, it appears that plant sterols are not retained within the intestinal lumen or enterocytes and do not prevent the absorption of previously ingested dietary cholesterol. Finally, the study population is also an important limitation in the context of its clinical implications. Subjects involved in this study were middle-aged males and postmenopausal females. Study subjects were overweight with borderline high levels of LDL cholesterol who were not taking any drug known to affect lipid metabolism. The study population in this study may have responded differently to some of the parameters measured, compared with the general population. Therefore, results obtained in this study may be representative of middle-aged adults with moderate hypercholesterolemia, and hence care must be taken in extrapolation of these results to other individuals such as obese and/or diabetic subjects. Another concern is the effect of the genetic make up of subjects on the responsiveness of LDL levels to different frequencies of plant sterol intervention. Few studies have looked at genetic variation in genes involved in sterol metabolism and heterogeneity in plasma plant sterols and LDL responsiveness to dietary intervention with plant sterol-enriched products. Apolipoprotein E phenotype, which has been shown to be correlated with cholesterol absorption (Kesaniemi et al., 1987) , has been reported to affect plant sterol cholesterol-lowering efficacy in one study (Vanhanen et al., 1993) , but not in others Hallikainen et al., 2000b) . In the other work, the genotype of apolipoprotein A-IV, scavenger receptor BI, 3-hydroxy-3-methyl-coenzyme A reductase and cholesterol ester transfer did not affect cholesterol-lowering effects of plant stanol . In response to dietary plant sterols, the T400K variant in ABCG8 accounted for differences in serum sterol concentration and predicted the subject responsiveness to changes in serum sterols, but not serum lipoprotein profile (Plat et al., 2005) . Unfortunately, due to the limited sample size, we were not able to further explore the effect of single-nucleotide polymorphisms.
In summary, results from this study indicate that dosing frequency of plant sterols may affect their action as cholesterol-lowering agents. Consumption of 1.8 g/day of plant sterols distributed over the day was more effective in lowering LDL cholesterol than the same dose once a day with breakfast, in spite of a reduction in cholesterol-absorption efficiency. Moreover, cholesterol FSR increased when plant sterols were consumed in divided doses, which may be attributed to feedback upregulation of cholesterol FSR in response to reduced sterol absorption. Present data indicate that to obtain optimal cholesterol-lowering impact, plant sterols should be consumed as smaller doses given more often, rather than one large dose. Therefore, health claims that are to be issued for the consumption of plant sterols/ stanols should be based on clinical trials with dosing regimens that mirror real-life usage of such materials.
